Agenus Inc Earnings

The next earnings date for Agenus Inc has not yet been scheduled.

Analyst Estimates of Agenus Inc Earnings

No Results.
Report DateEstimated Earnings Per Share
No Results.

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Agenus Inc Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
05/05/2025Before Market$-1.0347.98%
03/12/2025Before Market------
11/05/2024Before Market$-3.08-32.19%
08/08/2024Before Market$-2.52-75.00%
05/07/2024Before Market$-3.045.59%
03/14/2024Before Market$-0.13-160.00%
11/07/2023Before Market$-0.1615.79%
08/08/2023Before Market$-0.200.00%
05/09/2023Before Market$-0.22-4.76%
03/14/2023Before Market$-0.24-9.09%
11/08/2022Before Market$-0.190.00%
08/09/2022Before Market$-0.1726.09%
05/10/2022Before Market$-0.1936.67%
03/01/2022Before Market$-0.26-62.50%
11/09/2021Before Market$0.6950.00%
08/09/2021Before Market$-0.37-54.17%
05/06/2021Before Market$-0.2712.90%
03/15/2021Before Market$-0.209.09%
10/29/2020Before Market$-0.28-7.69%
08/06/2020Before Market$-0.28-3.70%
05/07/2020Before Market$-0.316.06%
03/12/2020Before Market$-0.2242.11%
11/04/2019Before Market$-0.3313.16%
08/08/2019Before Market$-0.38-15.15%
05/09/2019Before Market$0.12141.38%
03/14/2019Before Market$-0.40-42.86%
11/06/2018Before Market$-0.29-16.00%
08/09/2018Before Market$-0.2440.00%
05/07/2018Before Market$-0.42-40.00%
03/15/2018Before Market$-0.35-20.69%
11/07/2017Before Market$-0.37-8.82%
08/03/2017Before Market$-0.3213.51%
05/04/2017Before Market$-0.1833.33%
03/09/2017Before Market$-0.300.00%
10/27/2016Before Market$-0.47-56.67%
07/28/2016Before Market$-0.332.94%
04/28/2016Before Market$-0.37-68.18%
03/03/2016Before Market$-0.18-5.88%
10/27/2015Before Market$-0.160.00%
07/23/2015Before Market$-0.53-253.33%
04/23/2015Before Market$-0.28-2,700.00%
02/26/2015Before Market$-0.41-156.25%
10/31/2014Before Market$-0.1313.33%
07/24/2014---$-0.1225.00%
05/08/2014---$-0.0192.31%
03/05/2014---$-0.1633.33%
10/24/2013---$-0.247.69%
07/25/2013---$-0.40-81.82%
04/24/2013---$-0.35-59.09%
02/28/2013---$-0.234.17%
10/25/2012---$-0.2417.24%
08/02/2012---$-0.31-14.81%
04/25/2012---$0.29203.57%
03/05/2012---$-0.29-3.57%
10/27/2011---$-0.280.00%
07/28/2011---$-0.300.00%
04/28/2011---$-0.30-25.00%
02/17/2011---$-0.1840.00%
10/28/2010---$-0.360.00%
07/29/2010---$-0.300.00%
04/29/2010---$-0.60-66.67%
02/18/2010---$0.12122.22%
10/29/2009---$-0.78-18.18%
07/30/2009---$-20.16---
05/07/2009---$-0.84-16.67%
02/19/2009---$0.48150.00%
11/05/2008---$-1.025.56%
07/31/2008---$-1.14-5.56%
05/01/2008---$-1.20-42.86%
02/21/2008---$-0.9630.43%
11/01/2007---$-1.50-8.70%
08/02/2007---$-1.320.00%
05/08/2007---$-23.22---
02/21/2007---$-1.56-23.81%
10/31/2006---$-1.44-7.46%
08/01/2006---$-1.86-30.99%
05/03/2006---$-2.16-2.86%
02/23/2006---$-2.349.30%
10/27/2005---$-2.2811.63%
07/28/2005---$-2.82-15.57%
05/05/2005---$-2.40-2.13%
02/24/2005---$-2.285.00%
10/19/2004---$-2.465.02%
07/22/2004---$-0.4279.21%
04/20/2004---$-2.460.81%
02/19/2004---$-2.76-6.56%
10/23/2003---$-2.70-11.11%
07/23/2003---$-2.52-5.00%
04/16/2003---$-2.1623.40%
02/19/2003---$-2.94-13.51%
10/23/2002---$-2.400.83%
07/25/2002---$-2.40-4.35%
04/23/2002---$-2.220.00%
02/20/2002---$-2.40-2.56%
10/23/2001---$-2.40-25.00%
07/24/2001---$-1.86-8.77%
04/24/2001---$-1.620.00%
02/21/2001---$-3.72-129.63%
10/26/2000---$-1.1413.64%
07/25/2000---$-1.20-8.11%
04/24/2000---$-1.14-5.56%

More About Agenus Inc

Website
https://www.agenusbio.com
Country
USA
Full Time Employees
316

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

“Agenus Inc Earnings” Can Refer to the Agenus Inc Earnings Date

Some people say “Agenus Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Agenus Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Agenus Inc Stock on the Earnings Date

If you own Agenus Inc stock (AGEN) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Agenus Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Agenus Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Agenus Inc Earnings

You can contact us any time if you would like to ask questions about Agenus Inc earnings or anything else related to the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.